GenWay Biotech Obtains CLIA Certification
Main Category: Pharma Industry / Biotech IndustryArticle Date: 16 Jul 2009 - 0:00 PDT
| Patient / Public: | ![]() |
5 (2 votes) |
| Healthcare Prof: | ![]() |
4.75 (4 votes) |
GenWay Biotech, Inc., a US-based diagnostic company has become CLIA certified and received a California lab license. Their license currently permits the testing of immunological biomarkers. This is a very important step in the direction of commercialization of the novel innovative diagnostic tests currently being developed at GenWay. In upcoming weeks, GenWay will add new cancer biomarker tests to their portfolio as well as several infectious diseases such as sexual transmitted diseases. GenWay is seeking to obtain CAP accreditation by the end of the year.
Dr. Joe Voland, CLIA Pathologist and lab director, claims that he has never seen a CLIA lab get set up so efficiently and professionally as GenWay has done. GenWay Biotech Inc. is a GMP compliant facility with capabilities for research, development and manufacturing of proteins, antibodies, immunoassays, and diagnostics. Consequently, most quality control and assurance measures were already in place facilitating the transition into a CLIA certified laboratory. Furthermore, GenWay's lab is under construction for the addition of a Class 10,000 clean room which should be complete sometime in August 2009.
Dylan Malayter, Project Manager, who has played a predominant role in guiding the lab through the CLIA certification process, feels "This is an immense step forward for GenWay Biotech, Inc. We are excited to begin accepting patient samples and performing revolutionary tests that may save patients lives and enhance their treatment by monitoring their condition with simple non-invasive blood tests."
The GenWay team is looking forward to the future impact of the cancer biomarker tests they will offer. They have secured exclusive rights to the DR-70 test from AMDL and have secured several other biomarkers in the field of cancer diagnostics.
Source:
Dr. Jill Dombrauckas
GenWay Biotech
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/157638.php>
APA
http://www.medicalnewstoday.com/releases/157638.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



